XtalPi Holdings Limited 2228
HKEX · Hong Kong SAR China · Health Technology
HKD 8.18+0.29 (+3.68%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
XtalPi (HKEX: 2228), an AI- and robotics-driven drug and materials discovery company, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for KQTD-126. Developed internally, the candidate is a potential first-in-class gut-restricted pan-tropomyosin receptor kinase (pan-TRK) inhibitor designed to treat chronic intestinal pain associated with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
XtalPi (HKEX: 2228) announced that Viva-Thera, a biotechnology company it incubated and backs as a strategic shareholder, has nominated a preclinical candidate (PCC) targeting the membrane-proximal external region (MPER) of HIV-1 gp41. The partners completed discovery and optimization in seven months by combining Viva-Thera's atomic-resolution structural research with XtalPi's AI drug design and automation platform.
Apex Intelligence has completed its angel and angel-plus funding rounds, raising nearly US$50 Million in total. The angel round was co-led by IDG Capital, LinkX Capital and XtalPi, with participation from Decent Capital, SEE Fund, Monad Ventures, and Winsoul Capital. The angel-plus round was co-led by Zhongguancun Science City Fund, SCGC, and Shanghai Engine Fund.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.